

Special Issue

Arrhythmic Risk Stratification in Cardiomyopathies

Message from the Guest Editors

Arrhythmic risk stratification in nonischemic cardiomyopathies remains challenging for the clinical cardiologist. In the past, ejection fraction has been the indicator for defibrillator implantation in primary prevention. However, today, we know that we need to go beyond ejection fraction. Scientific evidence has documented the importance of genetics and cardiac MRI in proper arrhythmic risk stratification, but there are still many gray areas in this setting. With this Special Issue, we ask you to share your experiences regarding proper arrhythmic risk stratification in patients with cardiomyopathy.

Guest Editors

Dr. Marisa Varrenti

De Gasperis Cardio Center and Transplant Center, Niguarda Hospital,
20126 Milan, Italy

Dr. Patrizio Mazzone

De Gasperis Cardio Center and Transplant Center, Niguarda Hospital,
20126 Milan, Italy

Deadline for manuscript submissions

30 October 2025



Journal of Cardiovascular Development and Disease

an Open Access Journal
by MDPI

Impact Factor 2.3
CiteScore 3.7
Indexed in PubMed



mdpi.com/si/213436

*Journal of Cardiovascular
Development and Disease*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcdd@mdpi.com

[mdpi.com/journal/
jcdd](https://mdpi.com/journal/jcdd)





Journal of Cardiovascular Development and Disease

an Open Access Journal
by MDPI

Impact Factor 2.3
CiteScore 3.7
Indexed in PubMed



[mdpi.com/journal/
jcdd](https://mdpi.com/journal/jcdd)



About the Journal

Message from the Editor-in-Chief

The primary goal of the *Journal of Cardiovascular Development and Disease* (JCDD, ISSN 2308-3425) is to provide cardiovascular scientists a platform to publish their work in a quick and efficient way. Topics can range from studies designed to decipher the events underlying early heart development to studies focusing on the origins of congenital and acquired heart disease. Papers submitted to JCDD undergo a fast, yet thorough, peer-review process. In this process, we will apply strict ethical policies and standards. JCDD guarantees fast dissemination of results to a large scientific audience

Editor-in-Chief

Prof. Dr. Thomas Brand
National Heart & Lung Institute, Imperial College London, South
Kensington Campus, London SW7 2AZ, UK

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cardiac and Cardiovascular Systems) /
CiteScore - Q2 (General Pharmacology, Toxicology and
Pharmaceutics)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 28.8 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).